Lumexa Imaging (NASDAQ:LMRI) Stock Rating Lowered by Wall Street Zen

Key Points

• Wall Street Zen downgraded Lumexa Imaging from “buy” to “hold,” while the broader analyst consensus remains “Moderate Buy” with a $16.00 price target.
• Lumexa shares opened at $11.58, up 1.2%, with a market capitalization of approximately $1.11 billion and a 52-week trading range of $6.45 to $19.45.
• Institutional investors expanded their exposure, including BlackRock’s newly acquired $15.8 million position, while Director Brett Brodnax purchased 35,000 shares at an average price of $7.25.

Lumexa Imaging (NASDAQ:LMRI - Get Free Report) was downgraded by Wall Street Zen from a "buy" rating to a "hold" rating in a note issued to investors on Saturday.

Other equities research analysts also recently issued reports about the stock. Barclays decreased their price objective on shares of Lumexa Imaging from $15.00 to $9.00 and set an "overweight" rating for the company in a research note on Wednesday, May 20th. Weiss Ratings upgraded shares of Lumexa Imaging from a "sell (e)" rating to a "sell (d)" rating in a report on Thursday, June 25th. One investment analyst has rated the stock with a Strong Buy rating, one has given a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus price target of $16.00.

Lumexa Imaging Stock Up 1.2%

LMRI opened at $11.58 on Friday. Lumexa Imaging has a 1 year low of $6.45 and a 1 year high of $19.45. The firm has a 50 day moving average price of $10.45 and a 200 day moving average price of $11.02. The company has a debt-to-equity ratio of 1.43, a quick ratio of 1.40 and a current ratio of 1.40. The company has a market cap of $1.11 billion and a PE ratio of -19.63.

Insider Activity at Lumexa Imaging

In related news, Director Brett Brodnax purchased 35,000 shares of Lumexa Imaging stock in a transaction that occurred on Tuesday, May 19th. The shares were purchased at an average cost of $7.25 per share, with a total value of $253,750.00. Following the transaction, the director owned 62,027 shares of the company's stock, valued at approximately $449,695.75. The trade was a 129.50% increase in their position. The purchase was disclosed in a filing with the SEC, which can be accessed through this link. Insiders own 0.70% of the company's stock.

Institutional Trading of Lumexa Imaging

Hedge funds have recently made changes to their positions in the company. BlackRock Inc. acquired a new position in shares of Lumexa Imaging during the second quarter worth $15,771,000. Deutsche Bank AG purchased a new position in shares of Lumexa Imaging in the second quarter valued at $209,000. Bank of New York Mellon Corp acquired a new stake in Lumexa Imaging during the 2nd quarter valued at $709,000. Bank of America Corp DE increased its stake in Lumexa Imaging by 1,855,116.7% during the 1st quarter. Bank of America Corp DE now owns 111,313 shares of the company's stock worth $957,000 after buying an additional 111,307 shares during the period. Finally, Janus Henderson Group PLC increased its stake in Lumexa Imaging by 5.4% during the 1st quarter. Janus Henderson Group PLC now owns 2,100,356 shares of the company's stock worth $18,063,000 after buying an additional 107,903 shares during the period.

About Lumexa Imaging

We are one of the largest national providers of diagnostic imaging services(1). Our platform is integrated, scalable and has a proven track record of creating value for our stakeholders. As of September 30, 2025, we and our affiliates operated the second largest(1) outpatient imaging center footprint in the United States. It spans 184 centers(2)across 13 states and includes eight joint venture partnerships with health systems. Our centers are in attractive metropolitan statistical areas (“MSAs”).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source